✦ LIBER ✦

Immunotoxins as tools for cancer immunotherapy

✍ Scribed by H.E. Blythman; F.K. Janser; P. Casellas; O. Gross; H. Vidal

Publisher: Elsevier Science
Year: 1982
Tongue: English
Weight: 81 KB
Volume: 4
Category: Article
ISSN: 0192-0561
DOI: 10.1016/0192-0561(82)90075-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lentivirally transduced dendritic cells

Lentivirally transduced dendritic cells as a tool for cancer immunotherapy

✍ Karine Breckpot; Melissa Dullaers; Aude Bonehill; Sonja Van Meirvenne; Carlo Hei 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 348 KB

## Abstract ## Background Dendritic cells (DC) are the professional antigen‐presenting cells of the immune system, fully equipped to prime naive T cells and thus essential components for cancer immunotherapy. ## Methods We tested the influence of several elements (cPPT, trip, WPRE, SIN) on the t

Immunotoxins as cancer chemotherapeutic

Immunotoxins as cancer chemotherapeutic agents

✍ Clay B. Siegall; Edith A. Wolff; Susan L. Gawlak; Leland Paul; Dana Chace; Bruce 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 959 KB

Immunotherapy for cancer

✍ P. J. Guillou 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB

Levamisole as adjuvant immunotherapy in

Levamisole as adjuvant immunotherapy in breast cancer

✍ Annette D. Treurniet-Donker; Marlies L. Meischke-De Jongh; Wim L. J. Van Putten 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 350 KB 👁 2 views

Immunotoxins: New therapeutic reagents f

Immunotoxins: New therapeutic reagents for autoimmunity, cancer, and AIDS

✍ Ellen S. Vitetta 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 477 KB

Surgical adjuvant immunotherapy for colo

Surgical adjuvant immunotherapy for colorectal cancer

✍ Warren E. Enker; Janet L. Jacobitz; Karen Craft; Robert W. Wissler 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 550 KB

## Abstract One hundred forty‐four Wistar‐Furth rats in 12 therapeutic groups have been studied in a long‐term comparison of the effectiveness of nonspecific immunotherapy with MER (methanol extraction residue) vs active‐specific immunotherapy with neuraminidase‐modified tumor cells. Six months aft